Gastroparesis Drugs Market 2025: Future of Treatment Growth in U.S., Japan, GCC and MENA

gastroparesis drugs market reached US$ 7.50 billion in 2023 and is expected to reach US$ 10.96 billion by 2031, growing at a CAGR of 4.9% during the forecast period 2024-2031.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/gastroparesis-drugs-market?kb

United States: Recent Industry Developments

✅ September 2025: The FDA approved a novel prokinetic agent offering improved symptom relief for diabetic gastroparesis patients.

✅ August 2025: Clinical trials progressed for an oral ghrelin receptor agonist targeting enhanced gastric motility.

✅ November 2024: Pharmaceutical companies expanded patient access programs to increase availability of existing gastroparesis treatments.

GCC: Recent Industry Developments

✅ September 2025: Saudi Arabia's Ministry of Health launched awareness campaigns on gastroparesis diagnosis and management.

✅ July 2025: Regional hospitals in UAE introduced multidisciplinary clinics specializing in gastrointestinal motility disorders.

✅ December 2024: New partnerships formed between GCC pharma distributors and global drug manufacturers to improve drug supply chains.

MENA: Recent Industry Developments

✅ August 2025: Egypt and Jordan initiated clinical research collaborations focused on gastroparesis epidemiology and treatment outcomes.

✅ June 2025: Pharmaceutical import regulations eased in key MENA countries to facilitate faster access to gastroparesis medications.

✅ November 2024: Health authorities promoted training programs for healthcare professionals on gastroparesis management protocols.

Major Growing Players:

Aeromatic Healthcare, AstraZeneca Plc, Cadila Pharmaceuticals Ltd, Evoke Pharma, Neurogastrx, Inc., Teva Pharmaceutical Industries

Latest M&A

1. CinDome Pharma completes envision3D Phase II enrollment for deudomperidone (diabetic gastroparesis, Sep 2025); topline Q1 2026.​

2. Vanda Pharmaceuticals accepts FDA hearing for tradipitant NDA (Jan 2025).​
Strategic partnerships (Theravance velusetrag, Chugai GM-611, GSK camicinal, Processa PCS12852) advance without M&A.

Forecast Projection:

The Global Gastroparesis Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Global Gastroparesis Drugs Market report is built on solid intelligence - powered by both primary and secondary research. Our analysts have deep-dived into every factor that can influence your business roadmap, including government regulations, competitive landscape, tech innovations, historical market behavior, upcoming breakthroughs, adjacent industry trends, market volatility, growth prospects, and potential risks.

Government Regulations & FDA Approvals

FDA:

1. 2025 approvals; metoclopramide (Reglan) remains sole approved prokinetic (black-box warning); erythromycin off-label.​

2. IND clearances: Naronapride (Renexxion/Dr. Falk, Mar 2024) for dual 5-HT4/D2 action.​

3. Guidelines: AGA 2025 mandates 4-hour gastric emptying scintigraphy pre-therapy; diet + prokinetics first-line, G-POEM for refractory.​

Global: EMA/PRAC safety monitoring; no new EU approvals.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports): https://www.datamintelligence.com/buy-now-page?report=gastroparesis-drugs-market?kb

Key Segments:

By Drug Type: (Prokinetic Agents, Antiemetic Agents, Antianxiety Agents, Botulinum Toxin Injections, Others)

By Disease Type: (Diabetic Gastroparesis, Idiopathic Gastroparesis, Postsurgical Gastroparesis)

By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: sets the stage by defining the full scope of the report and delivering an executive summary of key market segments across regions, product types, and applications. It provides a comprehensive snapshot of current market sizes and reveals future growth potential, offering a clear vision of how the market will evolve in the short, mid, and long term.

Chapter 2: uncovers critical insights and highlights the most impactful emerging trends shaping the Gastroparesis Drugs market's future - essential knowledge for investors and strategists looking to stay ahead.

Chapter 3: dives deep into the competitive landscape, delivering an in-depth analysis of Gastroparesis Drugs manufacturers. It covers market share dynamics, strategic developments, and the latest mergers and acquisitions that are redefining the industry.

Chapter 4: profiles the market's leading players, offering detailed views of their revenue streams, profit margins, product portfolios, and recent innovations - arming you with the intel to benchmark and strategize effectively.

Chapters 5 & 6: break down revenue performance by region and country, providing a quantitative analysis that spotlights growth hotspots, development prospects, and the unique opportunities each market offers across the globe.

Chapter 7: explores market segmentation by type, revealing the size and untapped potential of each segment - guiding you toward lucrative "blue ocean" opportunities that competitors may have overlooked.

Chapter 8: analyzes the market by application, evaluating downstream sectors with the highest growth potential and identifying promising areas for expansion and investment.

Chapter 9: maps the entire industry supply chain, tracing upstream suppliers to downstream distributors, giving you full visibility into critical business linkages and value drivers.

Chapter 10: wraps up with a powerful summary of the report's key findings and strategic takeaways, delivering the must-know insights every industry stakeholder needs to make confident, forward-looking decisions.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/gastroparesis-drugs-market?kb

Supply Chain

1. Demand: Diabetic (60%+), idiopathic/post-surgical; hospitals lead distribution.​

2. Challenges: API shortages (China/India concentration), metoclopramide supply risks; clinical delays from reagents.​

3. Mitigation: Diversified manufacturing, stockpiles; pipeline oral/injectables reduce reliance on generics.

Have Detailed Enquiry of This Report @ https://www.datamintelligence.com/enquiry/gastroparesis-drugs-market?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.